Drug Discovery World

JANUARY 12, 2024

The first clinical trial participants have received doses of the ChAdOx1 NipahB vaccine at the University of Oxford. Despite the first outbreaks occurring 25 years ago in Malaysia and Singapore, there are currently no approved vaccines or treatments.

Virus 130

Virus Vaccine Trials Clinical Trials 130

Drug Discovery World

FEBRUARY 28, 2024

The first 20 participants have been enrolled in a multicentre trial to test whether ImmunityBio’s Nant Cancer Vaccine (NCV) could potentially prevent colon and other cancers in individuals with Lynch syndrome. The vaccine comprises a tri-valent Adenovirus (Tri-Ad5) in combination with the company’s IL-15 superagonist N-803.

Vaccine 130

Vaccine Trials Drugs Disease 130

PPD

JUNE 24, 2024

In the realm of vaccine development, mega trials — studies enrolling 5,000 subjects or more — have been instrumental in the fight against many pathogens, including influenza, rotavirus, malaria, RSV and most recently in the rapid development of vaccines against COVID-19.

Vaccine 97

Vaccine Trials Clinical Trials Laboratories 97

Drug Discovery World

MAY 30, 2024

DDW Editor Reece Armstrong speaks to Dr Katrina Pollock from the Oxford Vaccine Group at the University of Oxford. Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. RA: Could you tell us about the LEGACY03 trial?

Vaccine 147

Vaccine Protein Expression Clinical Trials Immune Response 147

Drug Discovery World

JUNE 6, 2024

The trial results also demonstrated an 81% reduction in risk of progression or death and 94% reduction in progression of brain metastases compared to Xalkori (crizotinib). The results of two ongoing Phase I/II clinical trials evaluating cancer immunotherapy epcoritamab, a T-cell engaging bispecific antibody, were shared at ASCO.

Drug Research 195

Drug Research Research Vaccine Clinical Trials 195

Drug Discovery World

JULY 31, 2024

A new facility at The University of Queensland, Australia, will provide researchers with cancer vaccines tailored to individual patients. Dr Seth Cheetham, Deputy Director of AIBN’s BASE facility, said: “Personalised mRNA cancer vaccines are now being used to train the body’s immune system to recognise and eradicate cancer cells.

Vaccine 147

Vaccine Clinical Trials Hospitals Treatment 147

Drug Discovery World

DECEMBER 6, 2022

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial. . The Phase I trial (IAVI G001) tested the first stage in a multi-stage HIV vaccine regimen the researchers are developing.

Vaccine 130

Vaccine Trials Clinical Trials Virus 130

Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.

Vaccine 130

Vaccine Regulations Trials Immune Response 130

Drugs.com

SEPTEMBER 4, 2024

4, 2024 -- Current vaccines against mpox were designed to fight an older, rarer cousin of the virus, smallpox.Now, new research from the drug company Moderna suggests its new mpox vaccine, based on mRNA technology, might do a. WEDNESDAY, Sept.

Vaccine 98

Vaccine Trials Virus Research 98

Drug Discovery World

JUNE 6, 2024

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. Ultimately it will contribute to survival rates improving continually over the next decades and more.” months after initial treatment.

Vaccine 147

Vaccine Clinical Trials FDA Approval Research Laboratories 147

Drug Discovery World

APRIL 13, 2023

The R21/Matrix-M malaria vaccine has received regulatory clearance for use in Ghana by the country’s Food and Drugs Authority, making it the first country to approve the vaccine. The vaccine has been approved for use in children aged five to 36 months, the age group at highest risk of death from malaria.

Vaccine 246

Vaccine Clinical Trials Trials Production 246

Drug Discovery World

APRIL 15, 2024

Naobios has signed a partnership agreement with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its Phase II clinical trials. At the end of 2022, the World Health Organization (WHO) reported that approximately 39 million people were living with HIV.

Vaccine 130

Vaccine Clinical Trials Trials Virus 130

Drug Discovery World

MAY 1, 2024

The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors. seed financing appeared first on Drug Discovery World (DDW).

Vaccine 147

Vaccine Clinical Trials Research Science 147

Drug Discovery World

AUGUST 15, 2022

A monoclonal antibody (mAb) treatment for the prevention of Malaria has shown encouraging results in a US Phase I clinical trial. . The mAb, known as L9LS, was developed by scientists at the National Institutes of Health’s (NIH) Vaccine Research Centre (VRC). Kenya, where malaria is endemic. . Official comments .

Vaccine 130

Vaccine Trials Clinical Trials Laboratories 130

Drug Discovery World

AUGUST 12, 2022

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . The trial will enrol up to 6,000 participants aged five years and older and will be conducted across 50 sites where Lyme disease is highly endemic. References .

Vaccine 130

Vaccine Disease Trials Pharmaceutical Companies 130

Drug Discovery World

APRIL 18, 2024

For the first time, a controlled human infection model for tuberculosis (TB) has been developed and could help with the future development of TB vaccines. The team states that it’s the first step towards establishing a challenge model that can be used to test new vaccines for TB.

Vaccine 130

Vaccine Clinical Trials Trials Disease 130

Drug Discovery World

MAY 15, 2024

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. Building protective vaccines before a pandemic emerges “We don’t have to wait for new coronaviruses to emerge.

Vaccine 130

Vaccine Immune Response Clinical Trials Virus 130

Drug Discovery World

SEPTEMBER 19, 2023

The University of Oxford has revealed that researchers are currently in the advanced stages of preparing for a clinical trial of a Nipah vaccine using the ChAdOx1 vector. There are currently no approved vaccines or treatments for Nipah virus infection. Seasonal outbreaks have occurred annually in Bangladesh since 2001.

Clinical Trials 162

Clinical Trials Virus Trials Vaccine 162

Drug Discovery World

FEBRUARY 8, 2023

A diversity study has shown that clinical trials should use real world diseases epidemiology data, rather than US Census Bureau race and ethnicity data, to ensure enrolment reflects the populations affected by different diseases. It also showed that GSK trial enrolment for each condition differed by race and ethnicity.

Clinical Research 242

Clinical Research Clinical Trials Research Trials 242

Drug Discovery World

OCTOBER 14, 2022

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The companies will report data from the ongoing Phase II trial of mRNA-4157/V940 in combination with KEYTRUDA in high-risk melanoma later this year. “We

Vaccine 244

Vaccine Research Laboratories Laboratories Clinical Development 244

Drug Discovery World

JANUARY 18, 2024

With funding from MRC/UKRI, the University of Oxford has assembled a team of scientists, radiologists and clinicians to research and understand the cause and effect of varying responses to vaccination. The results will assist researchers in designing vaccines which will offer greater protection to the most vulnerable.

Vaccine 130

Vaccine Clinical Research Hospitals Trials 130

Drug Discovery World

SEPTEMBER 22, 2023

The EU has historically been a leader in vaccine research, development and manufacturing, but is now seeing a decline in vaccine research, according to data published by Vaccines Europe (VE). However, the vaccines industry in the EU is also grappling with many challenges.

Vaccine 130

Vaccine Clinical Trials Trials Research 130

Drug Discovery World

OCTOBER 3, 2023

The R21/Matrix-M malaria vaccine has been recommended for use by the World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). The developers expect additional regulatory approvals will follow shortly and R21/Matrix-M vaccine doses could be ready to begin wider roll-out next year.

Vaccine 147

Vaccine Clinical Trials Licensing Licensing 147

Drug Discovery World

DECEMBER 18, 2023

An effective HIV vaccine may need to prompt strong responses from CD8+ T cells to protect people from acquiring HIV, according to a study from the National Institute of Allergy and Infectious Diseases (NIAID). Further tests revealed that this dampened response was due to reduced sensitivity to HIV of vaccine recipients’ T-cell receptors.

Vaccine 147

Vaccine Clinical Trials Laboratories Virus 147

Drug Discovery World

MARCH 27, 2024

The vaccines currently in late-stage development hold promise in tackling the disease burden of tuberculosis (TB), says data and analytics company GlobalData on World Tuberculosis Day 2024. According to GlobalData, there are 11 vaccines in late-stage development for TB globally.

Vaccine 130

Vaccine Clinical Trials Licensing Licensing 130

Drug Discovery World

AUGUST 24, 2022

The trial will see participants receive either a 14-day course of 600 mg tecovirimat twice daily or a matched placebo treatment. As a community-based trial, participants will take the treatment or placebo in their own homes. The trial looks to include at least 500 participants in the UK. .

Research 246

Research Clinical Trials Virus Trials 246

Drug Discovery World

JANUARY 9, 2023

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines. . The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. .

Research 130

Research Vaccine Government Clinical Trials 130

Drugs.com

OCTOBER 11, 2023

11, 2023 -- New research points to the potential of a COVID-19 vaccine delivered through the nose. The phase 1 clinical trial showed that the product, administered nasally in two doses, delivered a significant immune response to. WEDNESDAY, Oct.

Vaccine 114

Vaccine Trials Immune Response Clinical Trials 114

Drug Discovery World

SEPTEMBER 18, 2023

Jonathan Riess, lead investigator of the trial at the UC Davis Comprehensive Cancer Center, presented encouraging early clinical and biomarker data supporting the combination treatment for patients with metastatic non-small cell lung cancer (NSCLC). These data were presented at the IASLC 2023 World Conference on Lung Cancer (WCLC).

Vaccine 130

Vaccine Trials Therapies Treatment 130

Drug Discovery World

DECEMBER 22, 2022

Shelley McLendon , SVP of Vaccine and Infectious Diseases Program Management at ICON, attended the World Vaccine Congress Europe from 16-19 October 2022 in Barcelona, Spain. For instance, responsive clinical trials can use surveillance data to identify geographic areas and communities that are at high risk for disease.

Vaccine 130

Vaccine Disease Clinical Trials Trials 130

Drug Discovery World

DECEMBER 20, 2023

Centricity Research has acquired North Carolina-based Lucas Research, making it the fifth clinical research company to join Centricity since it launched in November 2021. With this acquisition, Centricity now has more than 35 clinical research sites, reaching 8.5 million geographically and ethnically-diverse patients.

Clinical Research 130

Clinical Research Research Clinical Trials Vaccine 130

Drug Discovery World

JUNE 6, 2023

The US Food and Drug Administration (FDA) has approved Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine Abrysvo in individuals 60 years and older. A vaccine to help prevent RSV had been an elusive public health goal for more than half a century.

FDA Approval 130

FDA Approval Virus Vaccine FDA 130

Drug Discovery World

AUGUST 7, 2023

A new Vaccine Development and Evaluation Centre (VDEC) has been unveiled in the UK, with the aim of building on the UK’s pandemic legacy and helping develop life-saving new vaccines that will fight ‘ Disease X ‘, a term used because what might trigger the next pandemic is unknown.

Vaccine 130

Vaccine Virus Clinical Trials Disease 130

Drug Discovery World

APRIL 3, 2024

In the last few years, immunotherapies like immune checkpoint inhibitors, vaccines and cell and gene therapies have revolutionised the treatment of cancer, and targeted drugs like monoclonal antibodies (mAbs), poly-ADP ribose polymerase (PARP) inhibitors and targeted protein degraders are also playing an important role.

Targeted Protein Degradation 130

Targeted Protein Degradation Research Therapies Drugs 130

Drug Discovery World

OCTOBER 26, 2023

Register for the DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, to hear insight and expertise from leading figures. The free two-hour summit will outline areas of opportunity in the oncology market and will feature insights from thought leaders in cancer research, precision medicine and immunotherapy.

Research 130

Research Vaccine Clinical Trials Science 130

Drug Discovery World

APRIL 16, 2023

Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. According to the results of the primary trial analysis, after 18 months, the RFS was 78.6%

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130

Drug Discovery World

JULY 27, 2023

Lineage Cell Therapeutics and Cancer Research UK have announced encouraging primary and secondary endpoint results from their clinical study of VAC2 in advanced non-small cell lung cancer (NSCLC). The post Topline results support allogeneic cell vaccine in lung cancer appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Clinical Trials Engineering Disease 130